Faculty Opinions recommendation of Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
Year: 2017
Type: peer-review
Abstract: Background-Short-term targeted treatment can potentially prevent fall asthma exacerbations while limiting therapy exposure.Objective-We sought to compare (1) omalizumab with placebo and (2) omalizumab with an inhaled corticosteroid (ICS) boost with regard to fall exacerbation rates when initiated 4 to 6 weeks before return to school.
Author: Johan Neyts
Institution: Rega Institute for Medical Research
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: U.S. Department of Health and Human Services, GlaxoSmithKline, Patient-Centered Outcomes Research Institute, University of Wisconsin-Madison, Massachusetts Medical Society, Mylan, National Institutes of Health, Genentech, Novartis Pharma, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Center for Research Resources, National Center for Advancing Translational Sciences
Awards: G11701374, UT Southwestern Center for Translational Medicine (UL1/KL2/TL1), Colorado Clinical and Translational Science Institute (UL1), G2332988543, Clinical and Translational Science Institute at Children's National, G4325039693, Effect of Atopy on Dendritic Cell Antiviral Responses, UT-Southwestern Clinical and Translational Alliance for Research (UT-STAR) (TL1), Multidisciplinary Clinical and Translational Science (MCTS) Program (UL1), G629043820, G6897685743, G7042479085, G7480681299, G7797485794, G8021174655, Clinical and Translational Science Award, Cincinnati Center for Clinical and Translational Sciences and Training, G896551248, G9000061460, G9000351588, Immune Tolerance Network, Colorado Clinical and Translational Science Institute (UL1)
OpenAlex ID: W4240130100